The urine samples’ targeted analytes that differentiated overall IC/BPS patients from controls included MCP-1 (OR 2.030), 8-OHdG (OR 1.687), 8-isoprostane (OR 1.557), Eotaxin (OR 1.141), and RANTES (1.012). The gene discussed is CCL5; the disease is Bartsocas-Papas syndrome 1.